Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy

Published: 14 February 2019| Version 1 | DOI: 10.17632/9g58y64x5d.1
Contributor:
Huijuan Wang

Description

Supplemental figure. The effect of EGFR-TKIs in patients with uncommon EGFR mutations showed a similar PFS, but OS was lower than in advanced lung adenocarcinoma patients with common EGFR mutations.

Files